Business Wire

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy ...

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the ...
Business Wire

OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong ...

Very good safety profile of OPM-101: no serious treatment-related adverse events occurred, and no discontinuation of the study was necessary Oral administration of OPM-101 demonstrated dose-related ...